Trophos, a French clinical stage pharmaceutical company developing therapeutics for indications in neurology and cardiology, has promoted Christine Placet to chief executive officer.
Placet has been cfo of Trophos since 2004. She becomes ceo with a mandate to continue to bring the Trophos’ ongoing programmes to a successful conclusion and to seek partnerships for Trophos’ advance-stage clinical development drug candidates, including Olesoxime, Olesoxime for Multiple Sclerosis (MS) disease progression, and TRO40303, which is in an ongoing Phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI).
Placet said: ‘There is considerable market potential of nearly US$2bn for the conditions targeted by our pipeline.’
Placet has more than 25 years' experience in a variety of areas of finance and business management. Prior to joining Trophos, she was cfo in a number of growing companies and start-ups in various industries, and worked as an auditor for eight years for Ernst & Young.
